Core Insights - Douglas Lane & Associates has increased its investment in Thermo Fisher Scientific by purchasing 16,745 shares valued at approximately $7.79 million, bringing its total holdings to 216,276 shares [2][11] - Following this purchase, Thermo Fisher Scientific accounts for 1.5% of the fund's reportable assets under management as of September 30, 2025 [3] Company Overview - Thermo Fisher Scientific reported a total revenue of $43.21 billion and a net income of $6.58 billion for the trailing twelve months [4] - The company has a dividend yield of 0.32% and its stock price was $534.68 as of October 9, 2025, reflecting a 12% decline over the past year [3][4] Business Performance - Thermo Fisher achieved a 3% revenue growth to $10.9 billion in its fiscal second quarter, with a 6% year-over-year increase in diluted earnings per share (EPS) to $4.28 [13] - The company has raised its fiscal guidance for 2025 to approximately $44 billion in sales, up from $42.9 billion the previous year [14] Investment Rationale - The current price-to-earnings (P/E) ratio of Thermo Fisher is lower than it was a year ago, suggesting that the stock is more attractively valued now [12] - The combination of rising revenue, increasing EPS, and a reasonable P/E ratio positions Thermo Fisher stock as a compelling buy opportunity [14]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Emerson Electric (EMR) , which belongs to the Zacks Manufacturing - Electronics industry, could be a great candidate to consider.This maker of process controls systems, valves and analytical instruments has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarte ...

MILFORD, Mass., Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 2nd, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instrume ...

Market Overview - The stock market experienced significant volatility in Q2 2025, with the S&P 500 reaching an all-time high by the end of June [1] - The market saw a drop of 7% from April 2 to April 7 due to the liberation day tariff announcement, followed by a rebound of over 22% from the April 7 low through the end of June [1] - The Russell 1000 Growth returned 17.8% and the S&P 500 returned 10.9% in the quarter, with large caps significantly outperforming small caps and growth outperforming value [1] Renaissance Large Cap Growth Strategy Performance - The strategy outperformed the S&P 500 Index but underperformed the Russell 1000 Growth benchmark [1] Company Focus: Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as an underperformer, with a one-month return of -0.11% and a 52-week loss of 21.70% [2] - As of September 09, 2025, Thermo Fisher's stock closed at $487.65 per share, with a market capitalization of $182.859 billion [2] - The company reported solid operating results but saw a decline of 18.5% in its stock price, attributed to lowered full-year guidance due to tariff-related macro weakness and uncertainty regarding NIH funding delays impacting academic and government customers [3]

Core Insights - Waters Corporation reported second quarter 2025 sales of $771 million, reflecting a 9% increase as reported and an 8% increase in constant currency compared to $709 million in the same quarter of 2024 [1][13] - The diluted earnings per share (EPS) for the second quarter of 2025 was $2.47, up from $2.40 in the second quarter of 2024, while non-GAAP EPS grew 12% to $2.95 from $2.63 [2][13] - The company is raising its full-year 2025 sales growth guidance to a range of +5.5% to +7.5% in constant currency and +5.0% to +7.0% reported [4][5] Financial Performance - The company achieved a net income of $147.1 million for the second quarter of 2025, compared to $142.7 million in the same quarter of 2024 [18] - Recurring revenue grew 11% in constant currency, with service growth at 9% and double-digit growth in chemistry [13] - The company reported operating income of $188.2 million for the second quarter of 2025, slightly down from $189.1 million in the same quarter of 2024 [17] Market and Product Insights - Instrument sales grew mid-single digits in constant currency, driven by high-single-digit growth in liquid chromatography (LC) and mass spectrometry (MS) [13] - The pharmaceutical market grew 11% in constant currency, while the industrial market grew 6%, and academic & government declined by 3% [13] - The company noted strong instrument replacement trends, particularly among large pharmaceutical and contract development and manufacturing organization (CDMO) customers [3] Guidance and Future Outlook - For the third quarter of 2025, the company expects constant currency sales growth in the range of +5.0% to +7.0% and reported sales growth of +4.5% to +6.5% [6] - Non-GAAP EPS for the third quarter of 2025 is projected to be in the range of $3.15 to $3.25, reflecting year-over-year growth of approximately +8% to +11% [6] - The company is well-positioned for future growth, particularly through its combination with BD Biosciences & Diagnostic Solutions, which is expected to enhance its strategy in high-growth adjacencies [3]

Core Viewpoint - Mettler-Toledo International reported strong Q2 2025 results, exceeding consensus expectations for both adjusted earnings per share and revenue despite facing challenges from tariffs, uneven demand, and rising costs [1][5][12] Financial Performance - Adjusted EPS (non-GAAP) was $10.09, surpassing the analyst estimate of $9.60, marking a 4.6% year-over-year increase [2][5] - GAAP revenue reached $983.2 million, exceeding the consensus of $957.6 million, reflecting a 3.8% year-over-year growth [2][5] - GAAP gross margin decreased to 59.0% from 59.7% in the prior year, while adjusted operating margin fell to 28.8% from 30.0% [2][6] - Net earnings (GAAP) declined to $202.3 million from $221.8 million year-over-year, a decrease of 8.8% [2][6] Business Overview - Mettler-Toledo International specializes in precision instruments for laboratory, industrial, and food retail applications, serving a diverse customer base including pharmaceutical, biotechnology, and food producers [3][4] - The company emphasizes maintaining market leadership through innovation and diversification across geographies and customer types [4] Strategic Developments - The company is focusing on supply chain restructuring to reduce exposure to tariffs and manufacturing costs, with an anticipated annualized tariff cost reduction from $115 million to $60 million [6][10] - R&D spending increased to $49.3 million, representing 5.0% of sales, aimed at developing new laboratory instruments and enhancing product offerings [7][8] Outlook - The company raised its full-year adjusted EPS forecast for fiscal 2025 to $42.10–$42.60, reflecting a 2–4% increase from the prior year [12] - Local currency sales are projected to grow 1–2% for fiscal 2025, with Q3 expectations of 3–4% growth [12] - Management plans to implement additional pricing actions and continue supply chain reforms to protect profit margins [13]

Company Overview - Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving various sectors including life sciences, materials, food, and environmental sciences for over 65 years [2] - The company ensures the efficacy of medicines, safety of food, purity of water, and quality and sustainability of everyday products [2] - Waters Corporation operates in over 100 countries with a workforce of more than 7,600 employees [2] Upcoming Financial Events - Waters Corporation will hold its Q2 2025 financial results conference call on August 4th, 2025, at 8:00 a.m. Eastern Time [1] - A live webcast of the presentation will be available on the Waters Investor Relations website, with a replay accessible until at least September 2nd, 2025 [1]

Group 1 - Waters Corporation will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th, 2025, at 8:45 AM Eastern Time [1] - A live webcast of the event will be available on the Waters Investor Relations website, with a replay accessible for 90 days [1] Group 2 - Waters Corporation is a global leader in analytical instruments, separations technologies, and software, serving various sectors including life sciences, materials, food, and environmental sciences for over 65 years [2] - The company employs over 7,600 individuals across more than 100 countries, collaborating with customers in laboratories, manufacturing sites, and hospitals [2] - Waters Corporation focuses on ensuring the efficacy of medicines, the safety of food, the purity of water, and the quality and sustainability of everyday products [2]

Core Insights - Waters Corporation reported first quarter 2025 sales of $662 million, a 4% increase from $637 million in the same quarter of 2024, and a 7% increase in constant currency [1][12] - The company achieved diluted earnings per share (EPS) of $2.03 on a GAAP basis and $2.25 on a non-GAAP basis, reflecting a year-over-year growth of 2% in non-GAAP EPS, despite a five percentage point negative impact from foreign exchange [2][12] - The company raised its full-year 2025 guidance for constant currency sales growth to a range of +5.0% to +7.0% and non-GAAP EPS guidance to $12.75 to $13.05, indicating an expected year-over-year growth of approximately +8% to +10% [4][5][12] Financial Performance - First quarter 2025 sales growth was driven by an 11% increase in instrument sales in constant currency, particularly strong in the pharmaceutical and industrial markets [3][12] - The company reported net income of $121.4 million for the first quarter, compared to $102.2 million in the same period last year [23] - Operating income for the first quarter was $151.7 million, up from $133.8 million in the prior year [23] Guidance and Outlook - For the second quarter of 2025, Waters Corporation expects constant currency sales growth in the range of +5.0% to +7.0% and reported sales growth of +4.0% to +6.0% [6] - The projected non-GAAP EPS for the second quarter is expected to be between $2.88 and $2.98, representing a year-over-year growth of approximately +10% to +13% [6][24] - The company’s operational actions and improvements in foreign exchange are expected to mitigate the impact of tariffs and policy changes [3][12]